RGPIRIS_PA: Performance of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris

Sponsor
University Ghent (Other)
Overall Status
Terminated
CT.gov ID
NCT04040790
Collaborator
(none)
10
1
1
21.2
0.5

Study Details

Study Description

Brief Summary

Data from 15 healthy subjects will be recorded in two testing sessions spread on two days, using three lens designs (A, B and C). Before the measuring days, each subject will undergo an extra fitting session of a large-diameter scleral contact lens on the dominant eye, assessed by an experienced practitioner. The fitting data will be used to custom-make the three lens designs for each subject, thus ensuring their comfort and safety during the days of the experiments. During the experiment days baseline measurements will be obtained before and after pupil dilation and contact lens wear. During the first testing session data from the lens design A (reference lens without artificial iris) will be recorded. During the second testing session data from the lens designs B and C (lenses with artificial iris with different transmittances) will be recorded. In each testing session, contrast sensitivity and visual acuity will be evaluated and non-invasive imaging measurements will be undertaken (optical coherence tomography and slit lamp). A specific questionnaire will be given to the subject to assess comfort, light sensitivity, the horizontal visual angle and overall experience of the scleral lens and in combination with a pair of sunglasses category 3-4.

Condition or Disease Intervention/Treatment Phase
  • Device: Scleral contact lens without a passive artificial iris
  • Device: Scleral contact lens with a passive artificial iris with low contrast (<1:5)
  • Device: Scleral contact lens with a passive artificial iris with high contrast (>1:5)
  • Drug: Tropicamide and phenylephrine
N/A

Detailed Description

First, the participant will be subjected to an RGP scleral contact lens fitting session, then during the second and third visits the participant will be subjected to several non-invasive procedures specific to the study in order to assess contrast sensitivity and visual acuity using the fitted and uniquely fabricated investigational medical devices. The tests will be performed after eye drops are supplied to dilate the pupil of the subjects (eye drops: tropicamide and phenylephrine). Besides the clinical experiments, the participant will be given a specific questionnaire in order to assess comfort, light sensitivity, horizontal visual angle and overall experience of the investigational medical device and in combination with a pair of sunglasses category 3-4. The investigators will document the occurrence of any adverse events and specific side effects during Day 2 and 3 (testing sessions with the investigational devices) in order to effectively assess their safety.

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of Light Sensitivity and Visual Acuity Changes as Consequence of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris
Actual Study Start Date :
Sep 16, 2019
Actual Primary Completion Date :
Jun 22, 2021
Actual Study Completion Date :
Jun 22, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Healthy volunteers

15 healthy volunteers for trials with passive artificial iris

Device: Scleral contact lens without a passive artificial iris
Participants wear a scleral contact lens without a passive artificial iris (Design A) on the dominant eye to perform the baseline visual performance assessment
Other Names:
  • Control lens Design A
  • Device: Scleral contact lens with a passive artificial iris with low contrast (<1:5)
    Participants wear a scleral contact lens with a low contrast (<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
    Other Names:
  • Test lens Design B
  • Device: Scleral contact lens with a passive artificial iris with high contrast (>1:5)
    Participants wear a scleral contact lens with a low contrast (<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment

    Drug: Tropicamide and phenylephrine
    Participants receive pupil dilation eye drops on the dominant eye, after baseline measurement and before wearing the scleral contact lenses (Designs A, B and C)
    Other Names:
  • Pupil dilation eye drops
  • Outcome Measures

    Primary Outcome Measures

    1. Visual acuity assessment and comparison between Designs A, B and C by means of logMAR or equivalent value [5 months from fitting session]

      Compare visual acuity values obtained with different designs

    2. Contrast sensitivity assessment and comparison between Designs A, B and C by means of threshold percentage or equivalent value [5 months from fitting session]

      Compare contrast sensitivity values obtained with different designs

    Secondary Outcome Measures

    1. Device safety by comparing eventual adverse events with those found in scleral contact lenses [5 months from fitting session]

      Comparing adverse event of similar devices

    2. Correct fitting [5 months from fitting session]

      Taking and analyzing ocular coherence tomography (OCT) images and slit lamp observations to estimate the clearance

    3. Contact lens wear comfort, as assessed by subject data from questionnaires Rasch analyzed using a 4-Andrich ration scale model [5 months from fitting session]

      The subjective assessment will be carried out by means of questions on 3 content areas: lens comfort (3 questions), visual quality (4 questions) and general satisfaction with the lenses (3 questions).

    4. Visual acuity assessment and comparison between Designs B (low contrast) and C (high contrast) by means of logMAR or equivalent value [5 months from fitting session]

      Comparing visual acuity between Designs B and C

    5. Contrast sensitivity assessment and comparison between Designs B (low contrast) and C (high contrast) by means of threshold percentage or equivalent value [5 months from fitting session]

      Comparing contrast sensitivity between Designs B and C

    6. Horizontal visual angle [5 months from fitting session]

      Angle at which the volunteer can see his fingers move when extending the arm (same side as dominant eye), 0°=arm extended to the side; 90°=arm straight ahead

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age between 18 and 45 years old
    Exclusion Criteria:
    • Iris disorders (i.e. ocular albinism, coloboma, aniridia).

    • Known disease-related ocular surface problem (i.e. microbial keratitis).

    • Known ocular pathologies (except refractive disorders).

    • Coexistent ocular diseases impeding contact lens correction (i.e. glaucoma, previous ocular surgery).

    • Corneal scarring.

    • Low corneal endothelial cell count (< 1500 cells per mm2), with potential of corneal hypoxia-induced corneal edema induced by contact lens wear.

    • Wearing of contact lenses in the last 24 hours (prior to the interventions).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Ghent (UZGent) Ghent Belgium 9000

    Sponsors and Collaborators

    • University Ghent

    Investigators

    • Study Chair: Andres F Vasquez Quintero, Professor, University Ghent

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University Ghent
    ClinicalTrials.gov Identifier:
    NCT04040790
    Other Study ID Numbers:
    • RGPIRIS_PA
    First Posted:
    Aug 1, 2019
    Last Update Posted:
    Apr 27, 2022
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Ghent
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 27, 2022